Este sitio web utiliza tecnologías de seguimiento, como cookies, para brindar una mejor experiencia al usuario. Si continúa utilizando este sitio, entonces reconoce nuestro uso de tecnologías de seguimiento. Para obtener información adicional, consulte nuestra Política de Privacidad.
REGÍSTRESE
Recently, Cancer Research Institute CEO and Director of Scientific Affairs Jill O’Donnell-Tormey, Ph.D., appeared in two informative Facebook Live broadcasts to discuss current developments and challenges in cancer immunotherapy.
Last week, during the Second International Cancer Immunotherapy Conference (CICON16), O’Donnell-Tormey moderated a Q&A panel with renowned cancer immunology experts Elizabeth Jaffee, M.D., of Johns Hopkins Medicine and Philip Greenberg, M.D., of Fred Hutchinson Cancer Research Center.
Earlier this week, O’Donnell-Tormey sat down with Business Insider’s pharmaceutical and biotech reporter Lydia Ramsey to share the latest advancements in cancer immunotherapy, and highlight CRI’s role in pioneering and leading this vital new field of cancer treatment.
We are grateful for the continued opportunities to provide updates on cancer immunotherapy’s progress and promising future.
El mejor amigo del hombre podría ayudarnos a curar el cáncer
Read Next Article
Comuníquese con nosotros
Cancer Research Institute | National Headquarters 29 Broadway, Floor 4 | New York, NY 10006-3111
800-992-2623212-832-9376Directorio de Personal
Dr. Benjamin Vincent recaps highlights from Day 4 of the 2022 CRI-ENCI-AACR International Cancer Immunotherapy Conference, covering cancer vaccines and innovative technologies to study tumor immunity.
Dr. E. John Wherry dicusses cell therapies and the cancer ecosystem during Day 3 of the 2022 CRI-ENCI-AACR International Cancer Immunotherapy Conference (CICON22).